The first phase I/IB open monotherapy trial (ClinicalTrials.gov identifier: NCT05013554) of TED16925 will recruit patients with different solid tumors expressing HER2, including those with HER2-low BC. This evidence concerns the gene ERBB2 and breast cancer.